A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityLutz Müller, Larry P. Yotti, Robert J. Mauthe et al.|Regulatory Toxicology and Pharmacology|2006Cited by 461
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumFrank Dieterle, J. Eric McDuffie, Josef Ozer et al.|Nature Biotechnology|2010Cited by 406